Skip to main content
. Author manuscript; available in PMC: 2021 Aug 25.
Published in final edited form as: Cell Rep. 2019 Dec 3;29(10):3009–3018.e4. doi: 10.1016/j.celrep.2019.11.007

Figure 4. Targeting HIF-1a sensitizes cancer cells against mitochondrial complex I dysfunction.

Figure 4.

(A) Viability of wild-type (WT) and HIF-1a KO clones (HKO1&2) transfected with HIF-1a cDNA after exposure to 10 μM phenformin for 72 hrs.

(B) Representative flow-cytometric analysis of 7-AAD and annexin V staining of Hut78 cells treated with phenformin (10 μM) for 72 hrs with percentage of early and late apoptotic cells indicated in red.

(C) Immunoblots of whole-cell lysates of Hut78 wild-type (WT) and HIF-1a KO (HKO1&2) cells.

(D) Cell viability of indicated cells lines after treatment with phenformin (10 μM), metformin (5 mM) and/or HIF-1a inhibitor, PX-478 (30 μM), for 72 hrs.

(E) Cell viability of Hut78 and Toledo cells treated with rotenone (1 μM), oligomycin (1 μg/mL) for 72 hrs. All data presented as mean ± SD of at least triplicate measurements.